Physician profile
Debra L Bailey
NPI 1285622852
$2,988.53
in general payments reported to CMS, 2019-2025
21 companies · $603 in 2025
The $603 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $13.67 · 2021: $57.65 · 2022: $266 · 2023: $1,053 · 2024: $445 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,101.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $509.36 | 2019-2025 | Taltz, Ebglyss |
| Pfizer INC. | $424.58 | 2019-2025 | |
| Abbvie INC. | $406.15 | 2019-2025 | Skyrizi |
| Organogenesis INC. | $290.31 | 2023-2025 | Puraply, Novachor |
| Merz North America, INC. | $206.56 | 2022-2023 | Xeomin |
| Galderma Laboratories, L.P. | $178.38 | 2019-2025 | Nemluvio |
| Boston Scientific Corporation | $140.85 | 2023 | |
| Silk Road Medical, INC. | $133.43 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Helsinn Therapeutics (U.S.), INC. | $125.00 | 2019 | |
| Kerecis Limited | $109.01 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Abiomed | $101.47 | 2025 | |
| Biofrontera INC. | $71.00 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Strata Skin Sciences, INC. | $47.47 | 2024 | Xtrac |
| Arthrex, INC. | $45.00 | 2019 | |
| Incyte Corporation | $40.13 | 2025 | Opzelura |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elekta, INC. | $35.64 | 2025 | Flexitron Hdr |
| Sun Pharmaceutical Industries INC. | $30.91 | 2025 | |
| Dermavant Sciences, INC. | $29.54 | 2024 | Vtama |
| Amgen INC. | $27.91 | 2023 | Otezla |
| Verrica Pharmaceuticals INC. | $20.83 | 2025 | Ycanth |
| Arcutis Biotherapeutics, INC. | $15.00 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.